ACC 2019: Abbott touts reduced stroke, bleeding and pump-clotting in HeartMate 3 trial

Abbott (NYSE:ABT) yesterday presented data from a new trial of its HeartMate 3 left ventricular assist device, touting a reduced rate of strokes, pump-related blood clots and bleeding episodes at two years as compared with the previous generation HeartMate II.